Giving (Bits of) Your Self to Medicine

Author | Raymond De Vries

Illustration by Marco Melgrati

You are sitting in the hospital, waiting for a checkup or perhaps to have a mole removed. In filling out the paperwork — What medications you are taking? Are your emergency contacts up to date? — you encounter a question about what is to be done with "excess tissues or specimens" that may be removed during diagnosis or treatment. Are you willing to donate these leftover bits of yourself (stripped of your name, of course) for medical research? 

If you are inclined to answer, "Sure, why not?" you will join the majority of Americans who agree to donate. And hey, it may be your donation that leads to the long-sought cure for cancer! 

On the other hand, the request to use part of your body for research may give you pause. What, exactly, will be done with your donation? Can the biobank guarantee that your genetic information will not be shared with your insurance company? Will your donation be used to patent a new drug that will be sold back to you at an exorbitant price? 

These questions may soon become a lot more real for many of us. 

Progress in science and medicine depends on public trust in the research enterprise. If scientists violate that trust they risk losing public support — and funding — for their work. 

In January 2015, President Obama announced his Precision Medicine Initiative, or PMI, asking for $215 million to move medical care from a "one-size-fits-all" approach to one that tailors treatments to each person's genetic make-up. Obama sees precision medicine as "one of the greatest opportunities for new medical breakthroughs that we have ever seen," allowing doctors to provide "the right treatments at the right time, every time, to the right person." 

What does this have to do with you and your decision to donate your blood and/or tissue to medical research? A critical piece of Obama's PMI, which is now being implemented, is the creation of a "voluntary national research cohort" of 1 million people who will provide the "data" researchers need to make this big jump in medical care. Yes, among other things, those "data" include bits of blood and tissue that will help scientists find the link between genes, illness and treatments. 

Those who are skeptical of the PMI have pointed to several problems with the plan, but none have focused on the most fundamental question: How will we get 1 million people to donate pieces of themselves to research? Recognizing that there may be some reluctance to donate, the drafters of the initiative bent over backwards to assure future donors that their privacy will be "rigorously protected." 

But privacy is not the only worry for donors. We at the Center for Bioethics and Social Sciences in Medicine — together with colleagues from the Center for Ethics and Humanities in the Life Sciences at Michigan State University — asked the American public about their willingness to hand over bits of themselves to researchers. Data from our national survey, published in the Journal of the American Medical Association, reveal that while most Americans are willing to donate to biobanks, they have serious concerns about how we ask for their consent and about how their donations may be used in future research. 

We asked our respondents — a sample representative of the U.S. population — if they would be willing to donate to a biobank using the current method of "blanket consent" where donors are asked to agree that their tissue can be used for any research study approved by the biobank, "without further consent from me." A healthy majority agreed. But when asked if they would still be willing to give blanket consent if they were told that their specimens might be used "to develop patents and earn profits for commercial companies" that number dropped significantly. Willingness to donate also dropped when respondents were told that their specimen might be used to create bioweapons or to develop more safe and effective abortion methods. 

Should we take these moral concerns seriously? Progress in science and medicine depends on public trust in the research enterprise. If scientists violate that trust they risk losing public support — and funding — for their work. The Havasupai tribe of Arizona, for instance, banished all researchers after learning that DNA donated by tribe members for research on the genetics of diabetes was also used, without permission, for a study that undermined the tribal story of its origins by tracing the migration of Havasupai ancestors. The Havasupai are not unique. In our sample we found that lack of trust in scientists and scientific research was the strongest predictor of unwillingness to donate to a biobank. 

When you are sitting in the waiting room, contemplating the decision to donate some of your self, you should be assured that doing so will not violate your sense of what is good or moral. The "Proposed Privacy and Trust Principles" issued by the PMI in 2015 are a hopeful sign. They call for transparency about "how [participant] data will be used, accessed and shared," including "the types of studies for which the individual's data may be used." The PMI soon will be asking us to donate bits of ourselves, and, if these principles are honored, they will go a long way toward building the trust that biobanks, and precision medicine, need to succeed. 

Raymond De Vries, Ph.D., is co-director of U-M's Center for Bioethics and Social Sciences in Medicine, and a professor in the Department of Learning Health Sciences. 

More Articles About: Genetics gray matters Research biobanks precision medicine initiative center for bioethics and social sciences in medicine Data
Featured News & Stories Minding Memory with a microphone and a shadow of a microphone on a blue background
Minding Memory
Vision Impairment as a Risk Factor for Dementia
The population of older adults living with dementia is expected to swell to nearly 14 million by 2050 and is estimated to cost the US economy more than 500 billion each year. In the absence of a cure for Alzheimer's disease, the primary cause of dementia, there's interest in understanding modifiable risk factors. In theory, getting a handle on the modifiable risk factors for dementia, would enable public health efforts to reduce cognitive decline in dementia at the population level. We've come a long way in understanding the risk factors for Alzheimer's disease and other related dementias. However, there's still work to be done. In this episode, we'll speak with Dr. Josh Ehrlich, a researcher at the University of Michigan, who has examined vision impairment as a risk factor for dementia.
A family discussing their family's medical history at Thanksgiving
Health Lab
Why you need to discuss your family health history at Thanksgiving
The holidays are a great time to discuss your family's medical history. Learn the importance of discussing your family's health history & how to bring it up.
Minding Memory with a microphone and a shadow of a microphone on a blue background
Minding Memory
Dementia as a Global Challenge – the International Partners Study of the HRS
According to an estimate published in 2015, the global prevalence of dementia was projected to nearly triple between 2015 and 2050, growing from 46 million to over 130 million people globally. And of that worldwide share, 70% of those with dementia will be in low- and middle-income countries. Tackling and ideally preventing dementia requires a global perspective. In this episode, Matt & Donovan speak with Dr. Lindsay Kobayashi, a faculty member in the Department of Epidemiology at the University of Michigan School of Public Health whose research focuses on the social epidemiology of aging from a global perspective. Dr. Kobayashi introduces us to a whole new world of data available to help researchers tackle dementia as a global challenge.
Minding Memory with a microphone and a shadow of a microphone on a blue background
Minding Memory
Dementia at the End of Life
Over thirty percent of individuals living with dementia living in the US each year die either of or with dementia – and almost half of those enrolled in hospice have dementia. As with so many other types of healthcare, there are disparities in both who enrolls in hospice as well as the type of care these individuals receive after enrollment. In this episode, Matt & Donovan talk with Dr. Lauren Hunt from UCSF, an expert in hospice care for persons living with dementia, about dementia at the end of life.
Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast
Spreading Access to STI Healthcare for Partners
A study explores how to better provide resources to sexual partners of those with STIs. Visit Health Lab to read the full story
Minding Memory with a microphone and a shadow of a microphone on a blue background
Minding Memory
The Long-Term Care Data Cooperative: Your One Stop Shop for Nursing Home Data
In this episode, Donovan & Matt talk with health services researcher Betsy White from Brown University about a unique new resource for researchers called the Long-Term Data Cooperative, a provider-led data sharing collaboratory that puts together nursing home EHR data from EHR vendors that can be linked to Medicare claims. This powerful tool is made available to researchers through an online application process.